

Presentations at 2026 ESMO Congress

October 23–27, 2026

*All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Friday, October 23, 2026

Personalising vaccines using peptides, DNA, mRNA and more

Patrick Ott, MD, PhD

Special Symposium

Melanoma: From standard fit to bespoke care/Leon Auditorium
Hall 4 | 13:30-15:00

What oncologists should know about mRNA vaccines: Perspectives from the medical oncologist

Toni Choueiri, MD

Special Session

What oncologists should know about mRNA vaccines
Alicante Auditorium - Hall 6 | 15:15-16:00

The best is yet to come: Immune modulating approaches in neuro-oncology

Lakshmi Nayak, MD
(Chair)

Challenge Your Expert

Salamanca Auditorium - Hall 10 | 16:15-17:00

Saturday, October 24, 2026

1842O Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2- advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)

Antonio Giordano, MD, PhD
Presenting Author

Proffered paper 2

Breast cancer, early and advanced stage
Alicante Auditorium - Hall 6 | 8:30-10:00

LBA74 First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL04)

Pasi A. Jänne, MD, PhD
Discussant (Chair)

Rapid oral 1

NSCLC, metastatic
Almeria Auditorium - Hall 9 | 8:30-10:00

2631RO First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study

Pasi A. Jänne, MD, PhD
Discussant (Chair)

Rapid oral 1

NSCLC, metastatic
Almeria Auditorium - Hall 9 | 8:30-10:00

LBA53 Perioperative apalutamide (APA) plus androgen deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): PROTEUS Substudy

Mary-Ellen Taplin, MD
Senior Author

Proffered paper

Genitourinary tumours, prostate, penile and testis
Barcelona Auditorium - Hall 9 | 10:15-11:45

Presentations at 2026 ESMO Congress

October 23–27, 2026

*All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Saturday, October 24, 2026 (*continued*)

2RO Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting

Sara Tolaney, MD, MPH
Presenting Author

Rapid oral 1
Breast cancer, advanced stage
Almeria Auditorium - Hall 9 | 10:15-11:45

LBA3 Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

Jacob Sands, MD
Presenting Author

Presidential Symposium 1
Alicante Auditorium - Hall 6 | 4:30-5:15

Sunday, October 25, 2026

3586O First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study

Toni Choueiri, MD
Presenting Author

Proffered paper 2
Genitourinary tumours, renal and urothelial
Alicante Auditorium - Hall 6 | 8:30-10:00

Personalized cancer vaccines

Patrick Ott, MD, PhD

Educational Session
All about cancer vaccines
Almeria Auditorium - Hall 9 | 8:30-10:00

Optimising systemic therapy and sequence for stage I HER2-positive early breast cancer

Sara Tolaney, MD, MPH

Educational Session
Optimising Systemic Therapy and sequence for stage I HER2-positive early breast cancer
Almeria Auditorium - Hall 9 | 10:15-11:45

The modern oncologist: Leading teams in an era of complexity

Elizabeth Mittendorf, MD, PhD

Special Session
ESMO-ASCO: The evolving definition of the modern oncologist
Oviedo Auditorium - Hall 5 | 10:15-11:45

Presentations at 2026 ESMO Congress

October 23–27, 2026

*All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Sunday, October 25, 2026 (continued)

6900 Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD)

Nancy Lin, MD
Discussant

Proffered paper
CNS tumours
Murcia Auditorium - Hall 3 | 10:15-11:45

6910 A First in Human Phase 1 Study of Intrathecal Peptide-Pulsed Dendritic Cells for HER2+ and Triple Negative Breast Cancer Leptomeningeal Disease

Nancy Lin, MD
Discussant

Proffered paper
CNS tumours
Murcia Auditorium - Hall 3 | 10:15-11:45

3589RO Final protocol-prespecified analysis of the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab versus placebo in clear cell renal cell carcinoma (ccRCC)

Toni Choueiri, MD
Presenting Author

Rapid oral 2
Genitourinary tumours, renal and urothelial
Burgos Auditorium - Hall 3 | 14:45-16:15

3593RO Plasma Kidney Injury Molecule-1 (KIM-1) Dynamics During First-Line Immunotherapy With or Without Cabozantinib in Advanced Renal Cell Carcinoma (aRCC)

Wenxin (Vincent) Xu, MD
Presenting Author

Rapid oral 2
Genitourinary tumours, renal and urothelial
Burgos Auditorium - Hall 3 | 14:45-16:15

Monday, October 26, 2026

4449RO Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody–drug conjugate (ADC) resistance in metastatic breast cancer (MBC)

Paolo Tarantino, MD, PhD
Presenting Author

Rapid oral 2
Breast cancer, advanced stage
Alicante Auditorium - Hall 6 | 10:15-11:45

Challenges in the management of neuro-endocrine and small cell prostate cancer

Himisha Beltran, MD

Challenge Your Expert
Granada Auditorium - Hall 4 | 10:15-11:00

Evolving surgical strategies after neoadjuvant immunotherapy: What should change?

Ravindra Uppaluri, MD, PhD

Special Symposium
IO-based systemic therapy in head and neck cancers
Granada Auditorium - Hall 4 | 16:30-18:00

Presentations at 2026 ESMO Congress

October 23–27, 2026

*All times CEST/CET (Please note that the time zone will switch from CEST to CET between 24 and 25 October 2026, due to the end of daylight saving time.)



Dana-Farber
Cancer Institute

PRESENTATION

SPEAKER

SESSION/TIME

Monday, October 26, 2026 (*continued*)

LBA11 Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study

Joyce Liu, MD, MPH
Discussant

Presidential Symposium III
Alicante Auditorium - Hall 6 | 16:30-18:15